



HYTN INNOVATIONS

GMP PROCESSING
CANNABIS PRODUCT MANUFACTURING
PSYCHEDELIC DRUG DEVELOPMENT
PSYCOACTIVE AND PSCYCOTROPIC COMPOUND DEVELOPMENT

CORPORATE PRESENTATION 2025
CSE: HYTN

Who We Are

HYTN Innovations (HYTN) is a GMP certified Canadian company specializing in the development of psychoactive and psychotropic products.

HYTN supplies products for highly regulated applications including products for global medicinal, clinical and recreational markets.

What We Do

We are revolutionizing the delivery of natural medicines to patients worldwide.

HYTN formulates, manufactures, markets, and sells premium products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids. Our mission is to become the leading provider of these products in federally regulated markets worldwide. We achieve this by identifying emerging opportunities and leveraging our advanced development platform to rapidly introduce innovative products to market.

Global Reach

Internationally, HYTN serves as a pharmaceutical manufacturer and processor, transforming Canadian-grown cannabis flower into GMP-certified medicines for distribution in markets such as Australia, the United Kingdom, and Germany. We collaborate with Canadian cannabis producers to extend their reach to global clients and work with international distributors and pharmaceutical companies to develop and supply products tailored to their markets.

Canadian Operations

In Canada, HYTN manufactures, markets, and distributes a line of cannabis-infused beverages and Nano-Shots under the HYTN brand, powered by our proprietary Elevation Technology. Our products are available in major markets, including Ontario, Quebec, Alberta, British Columbia, Nova Scotia, Manitoba, Yukon, and the Northwest Territories, and are carried by most national cannabis retailers.

Other Projects

HYTN is also equipped to manufacture GMP-certified products from other restricted input materials, such as psilocybin-containing mushrooms, for both domestic and international markets. We partner with brands aiming to launch their products globally and work with international distributors to supply medicines containing restricted materials for special access programs, clinical trials, or prescriber use.

Company Highlights

By maximizing its capacity and capabilities HYTN is well positioned to realize revenues from legal medical and recreational markets while also developing long term clinical assets, Active Pharmaceutical Ingredients (API's) and New Chemical Entities (NCE's)



Strategically Positioned

HYTN possesses a unique suite of licenses and product registrations allowing it to rapidly innovate within a complex regulatory environment. HYTN's strategic advantage allows it to take advantage of changes in global demand for psychoactive compounds and position itself in recreational, medical and clinical markets.



World Class Manufacturing

HYTN's purpose-built production facility is GMP Certified by the TGA under the international PIC/S standard. The facility holds all available licenses and amendments issued by Health Canada under the Cannabis Act for the cultivation, possession, processing and sale of cannabis and a Controlled Drugs and Substances Dealers License.



Globally Viable

HYTN's recreational cannabis products are available across Canada, while products manufactured for physician's use have been distributed internationally. GMP Processing allows access to over 50 markets under the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-Operation Scheme.



Strong Revenue Path

HYTN is well positioned to realize revenues related to controlled drugs and related substances. HYTN has demonstrated excellent control of its cost base allowing for a clear path to positive cash flow and profitability. The company currently owns all its equipment and inventory and has no debt.



Experienced Team

HYTN is built by a team of proven operators experienced in developing, formulating, and commercializing products containing psychoactive and psychotropic ingredients for recreational and medical markets.

Licenses and Certifications

HYTN possesses a full suite of licenses, guaranteeing products are compliant and manufactured to the highest global standards



GMP Drug Establishment Certificate
Therapeutic Goods Administration,
Australia



Complies with the Good Manufacturing
Practice requirements of the PIC/S Guide
to Good Manufacturing Practice for
Medicinal Products – 1 May 2021)



cGMP Drug
Establishment Licence
Health Canada



EUR-Lex & EudraGMDP
Inclusion (in process)




Cannabis Research
Licence



Cannabis Standard
Cultivation Licence



Cannabis Standard
Processing Licence
Cannabis Medical Sales
Licence (with possession)



Cannabis Standard
Processing Licence
Amendment for sale for
all categories: Edibles,
extracts and topicals



Cannabis Provincial /
Territory Vendor
Qualified with all provinces
and territories



Controlled Drugs and Substances
Dealers Licence (CDSL)



Controlled Drugs and
Substances Precursor Licence

HYTN's quality system meets the requirements of the European Pharmacopoeia (Ph. Eur.), German Pharmacopoeia (Deutsches Arzneibuch, DAB), Australia's Therapeutic Goods Administration (TGA) TGO 93 and TGO 100, British Pharmacopoeia (BP)



Regulatory First Approach

HYTN is committed to a regulatory first approach to product development. The company is compliant with all Canadian laws, and laws of all countries in which it does business. HYTN does not participate in any product development activities with organizations that are regulatorily exempt.

HYTN is Certified GMP and complies with the Good Manufacturing Practice requirements of the PIC/S Guide to Good Manufacturing Practice for Medicinal Products.

Facility Overview

A custom-built facility designed for innovative & scalable manufacturing


The facility is capable of processing and producing a wide range of products, including:



GMP Processing
And packaging



Active Pharmaceutical
Ingredients



New Chemical
Entities



Beverages



Edibles



Emulsions



Topicals



Tissue Cultures



Tinctures

Facility Capacity and Capability

- GMP cannabis processing capacity of 5000Kg per month (GMP finished goods)
- Bulk GMP packaging and release
- Active pharmaceutical ingredient manufacturing including cultivation, extraction, isolation and formulation
- Finished consumer good and placebo manufacture
- Production capacity of 6,000 active ingredient infused beverage units per shift
- Production capacity of 10,000 active ingredient infused edibles per shift
- Active emulsion capacity of 50mg/ml with a bulk capacity of 400L per shift
- Laboratory capabilities including high-performance liquid chromatography, particle size and zeta



Diversification Across Multiple Market Segments

GMP Medical

HYTN's GMP certification makes it one of the only processors with the ability to process finished GMP cannabis goods for export. This capability allows the company to rapidly enter global markets and supports global manufacturing partnerships.

Pharmaceutical

HYTN has successfully developed and commercialized products for physician use. The company's unique suite of licenses allows for the rapid development of active ingredients and the manufacturing of both novel medicine and placebo products for clinical trial and special access permissions.

Recreational

HYTN is fully licensed under the Cannabis Act and is vendor qualified in all Canadian markets. The company has successfully listed and sold all classes of cannabis products and is well positioned to capitalize on new markets when legalization occurs.

HYTN's unique suite of licenses and product offerings allows it to capture revenue from Wholesale, Direct to Consumer, Medical and Business to Business sales channels. This diversification ensures revenue protection and long-term growth opportunities.

One of the Rare Few

926 Active Canadian Cannabis Licenses

17 With GMP Processing Capability

7 With CDSL Capability

5 With Drug Establishment License



HYTN is processing cannabis flower into GMP finished goods for international markets including the UK, EU and Australia

HYTN is the only company to be selling GMP cannabis products and developing drugs from psilocybin

Where GMP Matters



Global medical cannabis sales are expected to grow to USD \$43.72B by 2030¹. Most emerging markets have mandated good manufacturing practice requirements to import, manufacture, package and sell cannabis goods². HYTN is well positioned to commercialize markets with GMP requirements.

1 - Fortune Business Insights, 2024
2 - AAPS, 2021

Commercializing GMP Capabilities

HYTN Receives Order for GMP Cannabis Goods

Processing Only

HYTN Receives Cannabis from LP that
Requires Processing

GMP Wholesaling

HYTN Procures Cannabis Flowers to Meet
International Distributor Demand

HYTN Processes Cannabis
(Final Dry, Final Trim, Testing, Weight, Packaging Labeling, Final release)
into EU GMP compliant finished goods

Processing Only

HYTN Bills for Processing Fee to Cannabis
Supplier (Service Only) Price Target
= \$300-\$1000 / kg

GMP Wholesaling

HYTN Bills Wholesale Value to International
Distributor (Wholesale) Price Target
= \$3000-\$5000/kg

HYTN Exports GMP Goods to Destination Market

Growth in Medical Cannabis and Clinical Psychedelics

The global medical cannabis market and clinical psychedelics industry are undergoing substantial growth. HYTN possesses the licenses, expertise and track record to address both immediate and future global demands.



Global demand for medical cannabis goods is increasing.

HYTN well positioned to service global medical needs.

Increased therapeutic potentials for cannabis goods.

Cannabinoids and Psychedelics are two groups of chemical compounds that show promise in treating a range of medical conditions.

Investment in clinical trials is driving considerable segment growth and presents long term return potential.

Both compounds show significant promise in treating various conditions including depression, anxiety and PTSD.

Most markets are regulated by a common regulatory body and require stringent compliance and licensing to participate.



Rapid growth in clinical research surrounding psychedelics.

Overlap in capability and expertise allows HYTN to service clinical needs.

Increased therapeutic potentials and clinical applications.

Proprietary Elevation Technology[®]



HYTN has developed a proprietary active ingredient delivery technology allowing for an enhanced product experience. Elevation Technology[®] ensures consistent quality and improves the user experience of our products



HYTN's proprietary process creates clear, odorless, emulsions that blend flawlessly into finished products.



Elevation Technology[®] ensures rapid, predictable and consistent effects



HYTN's high-quality lipophilic actives are encapsulated in nano-sized droplets that are thermodynamically and kinetically stable. The reduced droplet size ensures increased absorption and enhanced bioavailability producing more rapid and predictable effects



Industry-Leading Elevation Technology[®] combines nano emulsification technologies with custom machinery and a proprietary process to deliver consistent and stable active emulsions



HYTN's formulations are stackable and predictable, allowing for a more consistent product experience than the majority of products currently on the market



Using state of the art testing and analytical equipment products containing Elevation Technology[®] are guaranteed safe and stable

Elevated Products

Emulsions infused with Elevation Technology®

HYTN's infused emulsions combine all-natural ingredients with our Elevation Technology® delivering heightened experiences

- 0 Calories
- 0 Carbs
- Sugar-Free
- Gluten-Free
- Natural Ingredients



HYTN's Edibles are a combination of all-natural ingredients and our Elevation Technology®, delivering an elevated edible experience.

- Gluten-Free
- Natural Ingredients
- Elevated Flavours



Our Team

HYTN's team is comprised of industry professionals with diverse backgrounds in CPG Manufacturing, Molecular Genetics, Cannabis Cultivation and Drug Manufacturing

Elliot McKerr - CEO

As the founder and president of the award-winning Electric Bicycle Brewing, Elliot understands the intricacies of building forward-thinking brands within a crowded market segment and is skilled at making his products stand out amongst competitors. Elliot's ability to analyze current trends has allowed him to work on a multitude of brands across various sectors; recently he has consulted on and managed ten product launches ranging from smaller craft brands to international scale co-pack manufacturing.

Jason Broome - COO

Jason holds a M.Sc. in Molecular Genetics and has more than 15 years experience in the Pharmaceutical industry, including 2 years as head of the RX Division for a leading dermatology company. Working within Medical Device, Pharmaceutical, Fertility and Cannabis industries, he has built and lead operational, regulatory and quality systems.

Prior to joining HYTN Jason co-founded and served as SVP - Operations and Chief Research and Innovation Officer at The Flowr Corporation (TSXV: FLWR)

Dr. Philippe Henry - Strategic Advisor

Dr. Philippe Henry (PhD) is a renowned cannabis researcher and former professor of evolutionary genetics, with expertise in predictive chemotyping. He uses advanced analytical techniques to create profiles of the chemical composition of cannabis and psychedelic substances, bringing transparency and consistency to the industry. With numerous leadership roles in his career, including former CTO at Digipath Labs and CSO at VSSL, he has founded several successful companies in the cannabis and related industries. Dr. Henry's work has been featured in many publications, and he has been invited to speak at conferences and events worldwide. He continues to push the boundaries of innovation in the rapidly-evolving cannabis and psychedelic space

Rick Brar - Strategic Advisor

An entrepreneur with unparalleled foresight and historic firsts in the cannabinoid industry. Established Brains as Brazil's first registered medical cannabis product. Partnered with the largest vitamin distribution company in the UK. Co-founder of Sun Pharm, successfully RTO'ed Bevo to create Canadian LP; a founding member of the CMC and CDPRG

Disclaimer

Cautionary Note Regarding Forward-Looking Information

These materials include forward-looking statements. Such statements are based on our current beliefs and expectations and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control. Forward-looking statements regarding HYTN which are subject to uncertainties and contingencies beyond our control include, but are not limited to the statements relating to the GMP commercialization plan and the success of its expansion and other marketing plans.

Although HYTN believes that the expectations reflected in these forward-looking statements are reasonable, such statements involve risks and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements.

Such risks and uncertainties include but are not limited to, the fact that HYTN and the companies in which it may invest are early-stage companies with limited operating history and resources, execution of business plan requires raising additional capital, the Cannabis market is highly regulated and those regulations and enforcement priorities of governmental authorities may change, the Cannabis market is highly competitive, technical advances in the industry as well as changing political and economic conditions present within the industry will impact the success of HYTN and the companies in which it invests. Actual results could differ materially from the statements reflected in the forward-looking information.





HYTN INNOVATIONS

www.hytn.ca

info@hytn.ca

1.866.590.9289